Results 201 to 210 of about 412,112 (380)

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

THE PREVALENCE, COURSE, AND CHARACTERISTICS OF CHRONIC ANEMIA AFTER HEART AND LUNG TRANSPLANTATION

, 1992
Beverley J. Hunt, Sheela Amin, Ozay Halil, Magdi H. Yacoub   +3 more
openalex   +1 more source

A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation

ESC Heart Failure, Volume 12, Issue 2, Page 1166-1175, April 2025.
A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.
Shuangshuang Zhu, Weihua Qiao, Yixuan Wang, Ying Zhou, Yin Xu, Shijie Wang, Tian Xia, Guohua Wang, Si Chen, Jiawei Shi, Nianguo Dong   +10 more
wiley   +1 more source

Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension

, 1994
Ko Bando, John M. Armitage, Irvin L. Paradis, Robert J. Keenan, Robert L. Hardesty, Hiroaki Konishi, Kanshi Komatsu, Keith L. Stein, Ajit N. Shah, Henry T. Bahnson, Bartley P. Griffith   +10 more
openalex   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS FOR PNEUMOCYSTIS CARINII INFECTIONS IN HEART-LUNG AND LUNG TRANSPLANTATION—HOW EFFECTIVE AND FOR HOW LONG?

, 1992
Mordechai R. Kramer, C Stoehr, Norman J. Lewiston, Vaughn A. Starnes, James Theodore   +4 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Role for inflammatory markers in predicting right ventricular failure in mechanical assist device recipients

ESC Heart Failure, EarlyView.
Abstract Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.
Abdul‐Fatawu Osman, Shane S. Scott, Ebubechukwu O. Ezeh, Evans Osuji, Israel O. Ailemen, Mohamed H. Derbala, Salil Kumar, Asvin M. Ganapathi, Daniel B. Sims, Ashrith Guha, Bryan A. Whitson, Sakima A. Smith   +11 more
wiley   +1 more source

Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis

ESC Heart Failure, EarlyView.
AIM This analysis provides a comparison of the efficacy of initial mono and combination therapy in patients with PAH and cardiovascular comorbidities or with risk factors of HFpEF (heart failure with preserved ejection fractioin).METHOD Data from the European COMPERA registry were used for a matched pair analysis.
Dirk Skowasch, Christine Pausch, Doerte Huscher, David Pittrow, Judith Wede, Fabian Kreimendahl, Stephan Rosenkranz, Stephan Beckmann, Matthias Held, Ekkehard Grünig, H. Ardeschir Ghofrani, Hans Klose, Andris Skride, Michael Halank, Stefan Stadler, Marion Delcroix, Anton Vonk‐Noordegraaf, Ralf Ewert, Grzegorz Kopec, Marius M. Hoeper, Karen M. Olsson   +20 more
wiley   +1 more source

Meta-analysis and systematic review of gout prevalence in the heart/lung transplantation population. [PDF]

Front Transplant
Chui B, Day R, Umashankar E, Abdel Shaheed C, Keogh A, Girgis L, Penglase R.   +6 more
europepmc   +1 more source